Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604280 | 0.74 | CYP17A1 (0.68) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL4907036 | 0.73 | LMNA (0.35) | MAPT | |
| SCHEMBL17701217 | 0.72 | DYRK1A (0.46) | MAPT | |
| SCHEMBL19219074 | 0.71 | CYP17A1 (0.69) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL5544362 | 0.71 | CYP2C9 (0.50) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL16033234 | 0.70 | MAPT (0.55) | CYP3A4CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL500888 | 0.69 | CYP2C9 (0.53) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL17701230 | 0.69 | PDPK1 (0.52) | CYP2A6RAB9ACYP1A2 | |
| SCHEMBL338810 | 0.69 | LTA4H (0.70) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL1464252 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709666-B1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS NV (NL) | 2021-07-14 | — | — | EP | disclosed |
| US-10004810-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| EP-3135277-A1 | PARASITE CONTROL AGENT OR PARASITICIDE | Nippon Soda Co., Ltd. (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20170035711-A1 | PARASITE CONTROL AGENT FOR PARASITICIDE | NIPPON SODA CO., LTD. (JP) | 2017-02-09 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| EP-2709666-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | Koninklijke Philips N.V. (NL) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012156918-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | CYP3A4 337/4885CYP2C9 305/4885CYP2E1 1229/4885 |
| US-20170035711-A1 | PARASITE CONTROL AGENT FOR PARASITICIDE | CTRL, RPL41, EPX | CYP3A4 286/4885CYP2C9 220/4885CYP2E1 73/4885 |
| US-10004810-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | CYP3A4 337/4885CYP2C9 305/4885CYP2E1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.